Infected pilonidal cyst antibiotic selection
Incision and drainage is the primary treatment for an abscess from pilonidal disease. [1] Antibiotics are generally reserved for patients with systemic inflammatory response or for cases with extensive surrounding cellulitis or other complicating features. [1]
Treatment initiation criteria
Systemic or extensive disease features support adjunctive antibiotics in addition to drainage. [1]
Antibiotic therapy is suggested when any of the following are present:
- Temperature >38.5°C, heart rate >110 beats/minute, or erythema extending >5 cm from the wound edge. [1]
- Poor response to incision and drainage. [3]
Antibiotic coverage goals
Empiric coverage should target Staphylococcus aureus, including MRSA, when MRSA is likely or when systemic or complicated features are present. [2]
Medication selection algorithm
For an otherwise healthy 18-year-old with an infected pilonidal cyst in which antibiotics are indicated, empiric therapy should include MRSA-active oral therapy using one of the following options: [2]
- Trimethoprim-sulfamethoxazole (TMP-SMX). [2]
- Clindamycin. [2]
- A tetracycline (doxycycline or minocycline). [2]
An agent without MRSA activity should not be selected when MRSA coverage is indicated. [2]
“Best” antibiotic choice when MRSA coverage is needed
For outpatient MRSA-active empiric therapy, TMP-SMX is an evidence-supported oral option (Class A, Level II) and is a reasonable first choice among the listed oral MRSA-active agents. [2]
Monotherapy versus combination therapy
Monotherapy with an MRSA-active agent is appropriate for abscess-associated SSTI when broad gram-negative or anaerobic coverage is not required by clinical context. [1]
Combination therapy directed at gram-negative and anaerobic organisms is reserved for infections after procedures involving the gastrointestinal tract, axilla, perineum, or female genital tract. [1]
Common pitfalls to avoid
- Antibiotics without incision and drainage for a true abscess provide limited benefit. [1]
- Failure to include MRSA coverage when MRSA is likely leads to undertreatment. [2]
Targets and duration of therapy
A brief course of adjunctive systemic antibiotics can be used when systemic features are present, such as 24–48 hours after initial management in appropriate patients, with reassessment thereafter. [1]